A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Pasireotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 15 Dec 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.